The decision to anticoagulate a patient with atrial fibrillation involves a balance between the risks of thromboembolism against those of haemorrhage, with both risks imperfectly predicted by even the best stratification scoring systems. Although warfarin reduces the risk of stroke in patients with atrial fibrillation, its use remains limited by several limitations. Apixaban is a […]
Tag: apixaban
Apixaban shows promise
Warfarin has been the primary treatment to mitigate the increased risk of stroke associated with atrial fibrillation for more than 40 years. However, up to 30% of patients are not suitable candidates for or are unwilling to receive warfarin therapy despite having a high risk of stroke. A host of new oral agents are now […]